Clinical Trials Update: Sept. 17, 2007
Depression Breast Cancer Lymphomas
(HealthDay News) -- Here are the latest clinical trials, courtesy of Thomson CenterWatch:
This is a 25-week study of the safety and effectiveness of Cymbalta (duloxetine) vs. an inactive placebo in people who are age 65 or older. Participants must meet established criteria for depression and must be in generally good physical health. Additional criteria apply.
The research site is in Chicago, Ill.
This study will evaluate a combination of the drugs gemcitabine (Gemzar), paclitaxel (Taxol) and bevacizumab (Avastin) in women with advanced breast cancer. Participants will continue to receive treatment as long as the study drugs are working to control the cancer, as determined by the study physician. Participation is voluntary and you may withdraw from the study at any time.
The research site is in Lakeport, Calif.
This study will evaluate the safety and effectiveness of enzastaurin, to determine if it prevents or delays relapse of diffuse large B-cell lymphoma. Study participation may last up to three years, in which you will be closely monitored by your study doctor and you may continue to see your current oncologist. Study related physical examinations, medical history review, laboratory tests, and study medication will be provided at no cost.
The research site is in Orlando, Fla.
Copyright 2007 Thomson CenterWatch. All rights reserved.